Alessandro Lozza

TL;DR: Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life.

TL;DR: Preliminary data indicate that the combination of Doxy-TUDCA stabilizes the disease for at least 1 year in the majority of patients with an acceptable toxicity profile.

TL;DR: The data demonstrate that the pathogenic mechanisms responsible for chronic inflammatory demyelination polyneuropathy are broad and may include dysfunctions at the nodes of Ranvier in a subgroup of patients and that autoantibody depletion and recovery of conduction block and distal motor amplitude suggest a nodo-paranodopathy.

TL;DR: Unexplained worsening of neurological dysfunction despite bortezomib discontinuation, with prominent motor involvement and CSF signs of inflammation, may be the clues to this complication.

TL;DR: A devised double-innervation technique allows to achieve a good grade of flap contraction as well as emotional smiling ability, and a wider number of operated patients are needed to confirm those initial findings.